Related Experiment Video
Updated: Aug 2, 2026
07:54
Rapid Analysis of Chromosome Aberrations in Mouse B Lymphocytes by PNA-FISH
Published on: August 19, 2014
17.3K
Double-hit Signature with TP53 Abnormalities Predicts Poor Survival in Patients with Germinal Center Type Diffuse
Joo Y Song1,2, Anamarija M Perry3, Alex F Herrera2,4
1Department of Pathology, City of Hope National Medical Center, Duarte, California. josong@coh.org.
Summary
Genomic analysis of diffuse large B-cell lymphoma (DLBCL) identified four subgroups with distinct survival outcomes. A new schema using genomic variables can risk-stratify GCB DLBCL patients for targeted therapies.
Area of Science:
- Hematology
- Genomics
- Oncology
Background:
- Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous malignancy.
- Identifying prognostic markers is crucial for optimizing treatment strategies.
Purpose of the Study:
- To perform detailed genomic analysis on de novo germinal center B-cell (GCB) DLBCL cases.
- To identify genomic characteristics associated with survival in patients treated with R-CHOP therapy.
Main Methods:
- Comprehensive genomic characterization including IHC, gene expression profiling (GEP), FISH, copy-number analysis, and targeted deep sequencing.
- Analysis of 87 de novo GCB DLBCL cases.
Main Results:
- Four distinct biologic subgroups with differential survival were identified, aligning with existing DLBCL genomic classifications.
- Patients with double-hit signature (without TP53 abnormalities) and without EZH2 mutation/BCL2 translocation showed excellent prognosis.
- TP53 inactivation combined with a double-hit signature indicated an extremely poor prognosis, validated in independent cohorts.
Conclusions:
- A practical schema utilizing genomic variables for risk-stratification of GCB DLBCL patients is proposed.
- This approach offers a promising method for identifying high-risk patients eligible for novel therapeutic interventions.
